Is Egrifta (Tesamorelin) Legal in Minnesota?

The Federal Legal Foundation for Tesamorelin

Egrifta (tesamorelin) is a prescription drug with full FDA approval, not a gray-area research chemical. The FDA granted approval on November 10, 2010, under NDA 022505, making tesamorelin the first growth-hormone-releasing factor (GRF) analogue to receive regulatory clearance in the United States. [1] Because it holds approved status, it is subject to standard federal prescription drug law under 21 U.S.C. § 503(b), meaning it can be dispensed only pursuant to a licensed practitioner's order.

Controlled Substance Status

Tesamorelin is not listed under any schedule of the federal Controlled Substances Act (CSA). [2] The Drug Enforcement Administration (DEA) has not scheduled it, distinguishing it from peptides such as certain anabolic agents that carry Schedule III classification. This means no DEA registration is required for a prescribing physician, and pharmacies do not need DEA Schedule II/III dispensing procedures to fill it.

FDA-Approved vs. Off-Label Use

The approved labeling restricts Egrifta to HIV-associated lipodystrophy in adults. [1] Physicians in Minnesota, like those in every other state, retain the legal authority to prescribe approved drugs off-label when clinical judgment supports it. The FDA's off-label prescribing framework is established in federal guidance and has been consistently upheld. Off-label use is common in endocrinology and does not constitute illegal practice on its own. What a prescriber cannot do is claim an unapproved indication in promotional or fraudulent billing contexts, which would raise separate legal exposure under the False Claims Act rather than drug-legality statutes.

Minnesota State Law: What Governs Tesamorelin Locally

Minnesota does not have a state-specific tesamorelin statute. The legal framework at the state level comes from three sources: the Minnesota Pharmacy Practice Act (Minn. Stat. § 151), the Controlled Substances Act (Minn. Stat. § 152), and the medical practice act administered by the Minnesota Board of Medical Practice. [3]

Minnesota Controlled Substances Schedules

Tesamorelin does not appear on Minnesota's Schedule I through V lists under Minn. Stat. § 152.02. [3] Human growth hormone (somatropin) itself is not a state-level controlled substance in Minnesota either, though it carries federal anabolic-steroid-adjacent cautions. Because tesamorelin is a GRF analogue rather than exogenous growth hormone, it falls outside the narrow federal ban on distributing growth hormone for non-approved uses found in 21 U.S.C. § 333(e), which targets somatropin specifically. Tesamorelin works by stimulating endogenous GH release, a mechanistically distinct pathway.

Minnesota Board of Pharmacy Requirements

The Minnesota Board of Pharmacy enforces both state pharmacy law and federal law within the state. [4] A licensed Minnesota pharmacy can dispense brand-name Egrifta upon receipt of a valid prescription. The pharmacist must verify the prescriber holds an active Minnesota license (or a valid out-of-state license recognized under telehealth provisions) and that the prescription meets standard completeness requirements under Minn. R. 6800.

Medical Practice Act and Prescriber Obligations

The Minnesota Board of Medical Practice requires that any prescribing, including off-label prescribing of tesamorelin, occur within the context of a legitimate physician-patient relationship. [5] Prescribers must document clinical rationale in the patient record. Minnesota does not require a separate state permit to prescribe or administer tesamorelin. Standard standard-of-care documentation, including a physical or telehealth evaluation before prescribing, satisfies board expectations.

Compounded Tesamorelin: The 503A and 503B Framework

Compounded tesamorelin is where the legal picture becomes more specific. The FDA approved Egrifta as a finished pharmaceutical, and the agency has historically scrutinized compounding of drugs that have approved commercial equivalents. Understanding 503A versus 503B rules is essential for any Minnesota patient or provider considering compounded tesamorelin.

503A: Patient-Specific Compounding

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a state-licensed pharmacy may compound a drug for an identified individual patient based on a valid prescription. [6] The compound must not be essentially a copy of a commercially available drug. Because brand-name Egrifta is commercially available, a 503A pharmacy compounding tesamorelin must have a documented clinical reason why the approved product does not meet that specific patient's needs (for example, a patient requiring a different concentration due to a medical condition affecting dose administration).

The FDA issued draft guidance in 2023 clarifying its enforcement priorities for compounded drugs that are essentially copies of approved products. [7] Minnesota pharmacies operating under 503A must comply with both federal guidance and state board standards. Violations can trigger FDA Warning Letters, state board action, or both.

503B: Outsourcing Facilities

Section 503B of the FD&C Act created a category of "outsourcing facilities" that may produce larger batches of compounded drugs without patient-specific prescriptions, provided they register with the FDA and comply with current good manufacturing practice (cGMP). [6] Tesamorelin compounded by a registered 503B outsourcing facility may be dispensed to Minnesota patients through a prescriber's order if the facility is in compliance with FDA registration and reporting requirements. Minnesota patients ordering from 503B facilities should verify active FDA registration status, which is searchable on the FDA's outsourcing facility list. [8]

FDA Bulks List and Tesamorelin

The FDA maintains lists of bulk drug substances that may or may not be used in compounding. Tesamorelin is not on the FDA's 503A Category 1 bulk substances list (substances that may be used) or Category 2 list (substances under evaluation). [9] That absence means compounding pharmacies using bulk tesamorelin API (active pharmaceutical ingredient) rather than the approved finished product rely on the argument that compounding from bulk is permissible because the finished drug is not a copy if clinically differentiated. This is a contested area. The FDA has not issued a specific final rule prohibiting bulk tesamorelin compounding, but the agency's general policy disfavors bulk compounding of drugs with approved equivalents. Any Minnesota provider ordering compounded tesamorelin should confirm the pharmacy's legal basis in writing.

How to Get Egrifta (Tesamorelin) in Minnesota

Getting a legal tesamorelin prescription in Minnesota follows a straightforward clinical path when pursued correctly. The steps below apply whether a patient is seeking brand-name Egrifta or a compounded formulation through a compliant pharmacy.

Step 1: Establish a Qualifying Clinical Indication

The clearest legal path is the FDA-approved indication: HIV-associated lipodystrophy with excess visceral abdominal fat. For that indication, Egrifta 2 mg subcutaneous daily is the standard regimen. Clinical trials EGRIFTA-001 and the Phase 3 study published in JAMA (N=412 HIV-positive adults) demonstrated a statistically significant reduction in visceral adipose tissue (VAT) area of 18.4 cm² vs. 0.5 cm² in the placebo group at 26 weeks (P<0.0001). [10]

For off-label use (for example, age-related GH deficiency symptoms in non-HIV patients), the prescriber must document the clinical rationale and conduct an appropriate evaluation including relevant labs such as IGF-1.

Step 2: Consult a Licensed Minnesota Prescriber

Minnesota patients can see an endocrinologist, internal medicine physician, or a telehealth provider licensed in Minnesota. Telehealth prescribing became broadly available in Minnesota following regulatory updates during 2020 and has been maintained since. [5] The prescriber must conduct an adequate evaluation, either in person or via a synchronous video visit, before issuing a tesamorelin prescription. Audio-only encounters may not meet Minnesota Board of Medical Practice standards for initial prescribing of non-controlled injectable drugs.

Step 3: Pharmacy Dispensing

For brand-name Egrifta, a Minnesota retail or specialty pharmacy can fill the prescription directly. Egrifta requires refrigeration at 2 to 8 degrees Celsius and reconstitution before injection. Some specialty pharmacies offer patient training on self-injection technique. Insurance coverage varies: Medicare Part D and many commercial plans cover Egrifta for the approved HIV-lipodystrophy indication, but prior authorization is nearly universal. [11]

For compounded tesamorelin, the prescribing physician must identify a 503A or 503B compliant pharmacy. The patient should ask the pharmacy for its state license number from the Minnesota Board of Pharmacy and its FDA outsourcing facility registration number if it claims 503B status. [4]

Step 4: Monitoring Requirements

Once tesamorelin therapy starts, the prescriber should monitor IGF-1 levels, fasting glucose, and HbA1c. The FDA-approved label warns that tesamorelin may cause glucose intolerance and new-onset diabetes. [1] The American Association of Clinical Endocrinology (AACE) guidance on growth hormone axis disorders recommends periodic IGF-1 monitoring to avoid supraphysiologic levels. [12] In clinical practice, IGF-1 is typically checked at 4 to 6 weeks after initiation and then every 6 months during stable therapy.

Telehealth and Online Tesamorelin Prescriptions in Minnesota

Minnesota allows telehealth prescribing for non-controlled drugs when the prescriber holds an active Minnesota license and completes an appropriate evaluation. [5] Several national telehealth platforms now list tesamorelin as part of peptide therapy menus, but patients should verify three things before ordering: the prescriber's Minnesota license status (searchable on the MN Board of Medical Practice public lookup), the pharmacy's compliance status, and whether the product is brand-name Egrifta or a compounded formulation. Prescriptions issued purely based on an asynchronous questionnaire without a live clinical encounter may not satisfy Minnesota Board of Medical Practice standards and could expose both prescriber and patient to legal risk.

Risks of Obtaining Tesamorelin Outside Legal Channels

Tesamorelin sold without a prescription, labeled as a "research peptide," or supplied by overseas sources operates entirely outside FDA oversight. [13] Such products have no verified identity, potency, or sterility. The FDA's import alert system allows agents to detain shipments of unapproved drugs at the border. A Minnesota resident receiving an unscheduled drug not for personal use could face state misdemeanor charges under Minn. Stat. § 151.37 for possession of a prescription drug without a valid prescription. The absence of a federal controlled-substance charge does not make such possession consequence-free at the state level.

Insurance Coverage and Cost Considerations in Minnesota

Brand-name Egrifta carries a high list price. As of 2024, the average wholesale price for a 30-day supply of Egrifta 2 mg is approximately $4,000 to $6,000. Theratechnologies operates a patient assistance program for qualifying HIV patients. [11] Commercial insurers in Minnesota, including UCare, HealthPartners, and Medica, generally cover Egrifta for HIV-lipodystrophy with prior authorization documentation including CD4 count, viral load history, and DXA or CT imaging confirming excess VAT. Off-label prescriptions for non-HIV indications face steeper coverage barriers and often require specialty tier exceptions or appeals.

Summary of Legal Status by Channel

The table below consolidates the legal status of different tesamorelin access routes for Minnesota patients.

| Access Channel | Legal Status in Minnesota | Key Requirement | |---|---|---| | Brand-name Egrifta (approved indication) | Fully legal | Valid prescription, licensed Minnesota pharmacy | | Brand-name Egrifta (off-label) | Legal under medical practice law | Documented clinical rationale, valid prescriber-patient relationship | | Compounded tesamorelin (503A) | Legal with restrictions | Patient-specific Rx, clinical differentiation from approved product | | Compounded tesamorelin (503B) | Legal if facility is FDA-registered | Prescriber order, FDA-registered outsourcing facility | | Bulk API "research peptide" (no Rx) | Not legal for human use | No valid pathway | | Imported tesamorelin (no FDA approval) | Not legal | Subject to FDA import alert detention |